Community-associated Meticillin-resistant Staphylococcus Aureus

Overview

Journal Lancet

Publisher Elsevier

Specialty General Medicine

Date 2010 Mar 9

PMID 20206987

Citations 594

Authors

Frank R DeLeo

Michael Otto

Barry N Kreiswirth

Henry F Chambers

Affiliations

Soon will be listed here.

Abstract

Meticillin-resistant Staphylococcus aureus (MRSA) is endemic in hospitals worldwide, and causes substantial morbidity and mortality. Health-care-associated MRSA infections arise in individuals with predisposing risk factors, such as surgery or presence of an indwelling medical device. By contrast, many community-associated MRSA (CA-MRSA) infections arise in otherwise healthy individuals who do not have such risk factors. Additionally, CA-MRSA infections are epidemic in some countries. These features suggest that CA-MRSA strains are more virulent and transmissible than are traditional hospital-associated MRSA strains. The restricted treatment options for CA-MRSA infections compound the effect of enhanced virulence and transmission. Although progress has been made towards understanding emergence of CA-MRSA, virulence, and treatment of infections, our knowledge remains incomplete. Here we review the most up-to-date knowledge and provide a perspective for the future prophylaxis or new treatments for CA-MRSA infections.

Citing Articles

The Ligand Binding Domain of the Cell Wall Protein SraP Modulates Macrophage Apoptosis and Inflammatory Responses in Infections.

Sun H, Li R, Wang T, Ding L Molecules. 2025; 30(5).

PMID: 40076391 PMC: 11901804. DOI: 10.3390/molecules30051168.

Molecular Epidemiology Clinical Manifestations, Decolonization Strategies, and Treatment Options of Methicillin-Resistant Infection in Neonates.

Rallis D, Atzemoglou N, Kapetaniou K, Giaprou L, Baltogianni M, Giapros V Pathogens. 2025; 14(2).

PMID: 40005530 PMC: 11858580. DOI: 10.3390/pathogens14020155.

Potent human antibodies against SpA5 identified by high-throughput single-cell sequencing of phase I clinical volunteers' B cells.

Wang W, Li X, Ou Y, Zhou J, Gu Y, Liu B iScience. 2025; 28(1):111627.

PMID: 39834865 PMC: 11743104. DOI: 10.1016/j.isci.2024.111627.

Cinnamaldehyde nanoemulsion decorated with rhamnolipid for inhibition of methicillin-resistant biofilm formation: and assessment.

Yin L, Guo Y, Xv X, Dai Y, Li L, Sun F Front Microbiol. 2025; 15():1514659.

PMID: 39777149 PMC: 11703839. DOI: 10.3389/fmicb.2024.1514659.

Versatile Porphyrin Arrangements for Photodynamic Therapy-A Review.

Glowacka-Sobotta A, Czarczynska-Goslinska B, Ziental D, Wysocki M, Michalak M, Guzel E Nanomaterials (Basel). 2024; 14(23).

PMID: 39683268 PMC: 11643599. DOI: 10.3390/nano14231879.

References

Markowitz N, QUINN E, Saravolatz L . Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992; 117(5):390-8. DOI: 10.7326/0003-4819-117-5-390. View

Tristan A, Bes M, Meugnier H, Lina G, Bozdogan B, Courvalin P . Global distribution of Panton-Valentine leukocidin--positive methicillin-resistant Staphylococcus aureus, 2006. Emerg Infect Dis. 2007; 13(4):594-600. PMC: 2725977. DOI: 10.3201/eid1304.061316. View

Coombs G, Pearson J, OBrien F, Murray R, Grubb W, Christiansen K . Methicillin-resistant Staphylococcus aureus clones, Western Australia. Emerg Infect Dis. 2006; 12(2):241-7. PMC: 3373111. DOI: 10.3201/eid1202.050454. View

Hongo I, Baba T, Oishi K, Morimoto Y, Ito T, Hiramatsu K . Phenol-soluble modulin alpha 3 enhances the human neutrophil lysis mediated by Panton-Valentine leukocidin. J Infect Dis. 2009; 200(5):715-23. DOI: 10.1086/605332. View

Rajendran P, Young D, Maurer T, Chambers H, Perdreau-Remington F, Ro P . Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother. 2007; 51(11):4044-8. PMC: 2151464. DOI: 10.1128/AAC.00377-07. View

Diep B, Stone G, Basuino L, Graber C, Miller A, des Etages S . The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus. J Infect Dis. 2008; 197(11):1523-30. DOI: 10.1086/587907. View

ROGERS D, TOMPSETT R . The survival of staphylococci within human leukocytes. J Exp Med. 1952; 95(2):209-30. PMC: 2212057. DOI: 10.1084/jem.95.2.209. View

Foster T . Immune evasion by staphylococci. Nat Rev Microbiol. 2005; 3(12):948-58. DOI: 10.1038/nrmicro1289. View

Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C . Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005; 49(6):2260-6. PMC: 1140485. DOI: 10.1128/AAC.49.6.2260-2266.2005. View

10.

Boyle-Vavra S, Ereshefsky B, Wang C, Daum R . Successful multiresistant community-associated methicillin-resistant Staphylococcus aureus lineage from Taipei, Taiwan, that carries either the novel Staphylococcal chromosome cassette mec (SCCmec) type VT or SCCmec type IV. J Clin Microbiol. 2005; 43(9):4719-30. PMC: 1234068. DOI: 10.1128/JCM.43.9.4719-4730.2005. View

11.

Bubeck Wardenburg J, Bae T, Otto M, DeLeo F, Schneewind O . Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med. 2007; 13(12):1405-6. DOI: 10.1038/nm1207-1405. View

12.

Herold B, Immergluck L, Maranan M, Lauderdale D, Gaskin R, Leitch C . Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA. 1998; 279(8):593-8. DOI: 10.1001/jama.279.8.593. View

13.

Schaffer A, Lee J . Vaccination and passive immunisation against Staphylococcus aureus. Int J Antimicrob Agents. 2008; 32 Suppl 1:S71-8. DOI: 10.1016/j.ijantimicag.2008.06.009. View

14.

Stapleton P, Shah S, Ehlert K, Hara Y, Taylor P . The beta-lactam-resistance modifier (-)-epicatechin gallate alters the architecture of the cell wall of Staphylococcus aureus. Microbiology (Reading). 2007; 153(Pt 7):2093-2103. PMC: 2063568. DOI: 10.1099/mic.0.2007/007807-0. View

15.

Miller L, Diep B . Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008; 46(5):752-60. DOI: 10.1086/526773. View

16.

Okuma K, Iwakawa K, Turnidge J, Grubb W, Bell J, OBrien F . Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol. 2002; 40(11):4289-94. PMC: 139674. DOI: 10.1128/JCM.40.11.4289-4294.2002. View

17.

Feil E, Enright M . Analyses of clonality and the evolution of bacterial pathogens. Curr Opin Microbiol. 2004; 7(3):308-13. DOI: 10.1016/j.mib.2004.04.002. View

18.

Noel G, Strauss R, Amsler K, Heep M, Pypstra R, Solomkin J . Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother. 2007; 52(1):37-44. PMC: 2223887. DOI: 10.1128/AAC.00551-07. View

19.

Udo E, Pearman J, Grubb W . Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect. 1993; 25(2):97-108. DOI: 10.1016/0195-6701(93)90100-e. View

20.

Shaw K, Poppe S, Schaadt R, Brown-Driver V, Finn J, Pillar C . In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother. 2008; 52(12):4442-7. PMC: 2592863. DOI: 10.1128/AAC.00859-08. View